Log In
BCIQ
Print this Print this
 

RLY6002

  Manage Alerts
Collapse Summary General Information
Company Galenica Ltd.
Description 
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationDiabetes
Indication DetailsAdjunct to diet and exercise to improve glycemic control in adults with Type II diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,500.0M

$1,500.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/02/2016

$1,500.0M

$1,500.0M

0

Get a free BioCentury trial today